Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
复制标题

DOI:
10.2967/jnumed.110.077941
复制
发表时间:
2011-01
期刊:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子:
--
通讯作者:
Jadvar H
Jadvar H
中科院分区:
其他
文献类型:
--
作者:
Jadvar H

文献摘要

参考文献

被引文献

相似文献

前列腺癌在生物学和临床上是一种异质性疾病,这使得影像学评估具有挑战性。影像学在前列腺癌中的作用应包括原发性肿瘤的诊断、定位和特征描述(惰性与致命性)、确定包膜外扩散、对局限性疾病的局部治疗进行引导和评估、局部区域淋巴结分期、在生化复发时检测局部复发和转移性疾病、放射治疗计划、预测和评估肿瘤对挽救性和全身性治疗的反应、监测积极监测情况并确定进行确定性治疗的触发因素,以及预测去势疾病中出现激素抵抗的时间和总体生存率。为了有效完成这些任务,影像学需要以针对患者个体、风险调整的方式适应疾病的特定阶段。在本文中,我回顾了关于正电子发射断层扫描(PET)在前列腺癌中潜在和新兴作用的临床前和临床证据,涉及3种最常研究的放射性示踪剂,即18F - 氟脱氧葡萄糖(18F - FDG)、18F - 或11C - 醋酸盐以及18F - 或11C - 胆碱。
Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. The role of imaging in prostate cancer should include diagnosis, localization, and characterization (indolent vs. lethal) of the primary tumor, determination of extracapsular spread, guidance and evaluation of local therapy in organ-confined disease, staging of locoregional lymph nodes, detection of locally recurrent and metastatic disease in biochemical relapse, planning of radiation treatment, prediction and assessment of tumor response to salvage and systemic therapy, monitoring of active surveillance and definition of a trigger for definitive therapy, and prognostication of time to hormone refractoriness in castrate disease and overall survival. To address these tasks effectively, imaging needs to be tailored to the specific phases of the disease in a patient-specific, risk-adjusted manner. In this article, I review the preclinical and clinical evidence on the potential and emerging role of PET with the 3 most commonly studied radiotracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
DOI: 10.1007/s00259-002-1104-y
发表时间: 2003-04-01
影响因子: 9.1
作者:
Fricke, E;Machtens, S;Boerner, AR
通讯作者: Boerner, AR
DOI: 10.1007/s11307-005-0023-2
发表时间: 2006-01-01
影响因子: 3.1
作者:
Heinisch, M;Dirisamer, A;Langsteger, W
通讯作者: Langsteger, W
DOI: 10.2967/jnumed.108.056713
发表时间: 2008-12-01
影响因子: 9.3
作者:
Hillner, Bruce E.;Siegel, Barry A.;Coleman, R. Edward
通讯作者: Coleman, R. Edward
DOI: 10.1007/s12149-008-0177-5
发表时间: 2008-11
影响因子: 2.6
作者:
Jadvar, Hossein;Ye, Wei;Groshen, Susan;Conti, Peter S.
通讯作者: Conti, Peter S.
DOI: 10.1016/j.nucmedbio.2006.08.002
发表时间: 2006-11-01
影响因子: 3.1
作者:
Hara, Toshihiko;Bansal, Aditya;DeGrado, Timothy R.
通讯作者: DeGrado, Timothy R.